Dare Bioscience, Inc. 8-K

What Happened

• Daré Bioscience (DARE) announced it completed the closing of its Regulation A offering on March 16, 2026. The offering was for Investor Units priced at $5.00 each. Daré issued 43,050 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock.

Key Details

• Offering type: Regulation A (Form 1-A, File No. 024-12688), qualified by the SEC on January 5, 2026; offering circular dated January 6, 2026.
• Units issued: 43,050 Investor Units at $5.00 each — gross proceeds of approximately $215,250.
• Securities issued: 43,050 shares of Series A Convertible Preferred Stock and Investor Warrants to purchase up to 86,100 shares of common stock (2 warrants per unit).
• Additional terms: Conversion and exercise terms were previously disclosed in Daré’s Form 8-K filed January 29, 2026, and are incorporated by reference.

Why It Matters

• This offering provided Daré with a modest capital infusion (about $215k) and creates potential future dilution if the issued preferred shares are converted and the warrants are exercised according to the offering terms.
• Investors should review the original Form 1-A offering circular and the Jan. 29, 2026 8-K for the specific conversion and exercise mechanics and any impact on share count or voting/financial rights.